Equillium, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $5.3 million, a decrease from the $8.7 million loss recorded in the same period of 2025. The company’s total operating expenses for the quarter were $5.6 million, down from $8.9 million year-over-year, primarily due to reduced research and development costs, which fell to $3.0 million from $5.9 million. This reduction is attributed to the winding down of clinical studies, particularly the EQUATOR study, and a decrease in employee compensation expenses linked to a lower headcount.
As of March 31, 2026, Equillium's cash and cash equivalents stood at $61.3 million, a significant increase from $30.3 million at the end of 2025. The company raised approximately $35 million through a private placement of common stock and pre-funded warrants in March 2026, which contributed to the cash increase. The total stockholders' equity rose to $59.5 million from $28.6 million at the end of the previous fiscal year, reflecting the successful capital raise and the issuance of additional shares.
Operationally, Equillium is focused on advancing its lead product candidate, EQ504, a novel aryl hydrocarbon receptor modulator, into clinical development. The company plans to initiate a Phase 1 proof-of-mechanism study for EQ504 in mid-2026, with data expected approximately six months thereafter. Additionally, Equillium has acquired exclusive worldwide rights to EQ504 through its acquisition of Ariagen, Inc. in October 2024, and it continues to explore the development of EQ302, a preclinical-stage product candidate targeting gastrointestinal diseases.
The company has not yet generated revenue from product sales, maintaining an accumulated deficit of $221.5 million as of March 31, 2026. Equillium anticipates continued operating losses as it invests in research and development activities. The company expects to finance its future operations through a combination of equity offerings, debt financings, and potential collaboration agreements. Management believes that the current cash reserves will be sufficient to fund operations into 2029, although they acknowledge the inherent uncertainties in clinical development timelines and costs.
About Equillium, Inc.
Equillium, Inc. is a biotechnology company focused on developing novel immuno-inflammatory therapeutics. Its pipeline includes first-in-class monoclonal antibodies and multi-cytokine inhibitors targeting severe autoimmune and inflammatory diseases such as graft-versus-host disease, celiac disease, and alopecia areata. The company leverages proprietary platforms and strategic partnerships to advance clinical candidates and aims to commercialize therapies that address high unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.